AIM:RENX

Stock Analysis Report

Executive Summary

Renalytix AI plc focuses on the development of artificial intelligence enabled clinical diagnostic solutions for kidney disease.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Renalytix AI's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RENX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

18.9%

RENX

14.3%

GB Healthcare Services

5.9%

GB Market


1 Year Return

54.4%

RENX

-21.2%

GB Healthcare Services

-22.7%

GB Market

Return vs Industry: RENX exceeded the UK Healthcare Services industry which returned -21.2% over the past year.

Return vs Market: RENX exceeded the UK Market which returned -22.7% over the past year.


Shareholder returns

RENXIndustryMarket
7 Day18.9%14.3%5.9%
30 Day-34.3%-17.1%-23.1%
90 Day-39.6%-21.3%-28.1%
1 Year54.4%54.4%-20.0%-21.2%-18.6%-22.7%
3 Yearn/a21.6%15.5%-13.4%-24.7%
5 Yearn/a44.8%32.4%1.3%-22.0%

Price Volatility Vs. Market

How volatile is Renalytix AI's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Renalytix AI undervalued compared to its fair value and its price relative to the market?

3.88x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RENX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RENX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RENX is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: RENX is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RENX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RENX is overvalued based on its PB Ratio (3.9x) compared to the GB Healthcare Services industry average (2x).


Next Steps

Future Growth

How is Renalytix AI forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

62.7%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if RENX's forecast earnings growth is above the savings rate (0.5%).

Earnings vs Market: Insufficient data to determine if RENX's earnings are forecast to grow faster than the UK market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RENX's revenue (62.7% per year) is forecast to grow faster than the UK market (2.6% per year).

High Growth Revenue: RENX's revenue (62.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RENX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Renalytix AI performed over the past 5 years?

-98.9%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: RENX is currently unprofitable.

Growing Profit Margin: RENX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if RENX's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare RENX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RENX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.6%).


Return on Equity

High ROE: RENX has a negative Return on Equity (-16.54%), as it is currently unprofitable.


Next Steps

Financial Health

How is Renalytix AI's financial position?


Financial Position Analysis

Short Term Liabilities: RENX's short term assets ($21.4M) exceed its short term liabilities ($1.3M).

Long Term Liabilities: RENX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: RENX is debt free.

Reducing Debt: RENX had no debt 5 years ago.


Balance Sheet

Inventory Level: RENX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if RENX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RENX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RENX has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of -66.6% each year.


Next Steps

Dividend

What is Renalytix AI's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RENX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RENX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RENX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RENX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RENX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

US$187k

CEO Compensation


CEO

James McCullough (51yo)

no data

Tenure

US$187,342

Compensation

Mr. James R. McCullough, MBA, has been Chief Executive Officer and Director of Renalytix AI plc. Mr. McCullough serves as Director at LungLife AI, Inc. (Cynvenio Biosystems, Inc). Mr. McCullough co-founded ...


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD187.34K) is below average for companies of similar size in the UK market ($USD758.23K).

Compensation vs Earnings: Insufficient data to compare James's compensation with company performance.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.5%.


Top Shareholders

Company Information

Renalytix AI plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Renalytix AI plc
  • Ticker: RENX
  • Exchange: AIM
  • Founded: 2018
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: UK£130.715m
  • Shares outstanding: 59.42m
  • Website: https://www.renalytixai.com

Number of Employees


Location

  • Renalytix AI plc
  • Avon House
  • 19 Stanwell Road
  • Cardiff
  • South Glamorgan
  • CF64 2EZ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RENXAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPNov 2018
RTNX.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDNov 2018

Biography

Renalytix AI plc focuses on the development of artificial intelligence enabled clinical diagnostic solutions for kidney disease. Its solutions are used in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was incorporated in 2018 and is headquartered in Cardiff, the United Kingdom. Renalytix AI plc operates independently of EKF Diagnostics Holdings plc as of November 2, 2018. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 00:24
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.